AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications

NEWPORT BEACH, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection, today announced the appointment of Chad K. Oh, M.D. as Chief Medical Officer, effective immediately. Dr....

Click to view original post